• Xspray Pharma AB (publ) will present two posters on Dasynoc and Nilopki at the John Goldman CML conference on Oct. 2-4, 2026.
• Dasynoc data point to more predictable drug exposure, supporting a lower-dose approach that could improve tolerability without sacrificing effectiveness.
• Nilopki results suggest reduced food-related variability, which could lower day-to-day safety uncertainty tied to nilotinib’s cardiovascular risk profile.
• The readouts support product differentiation as both candidates remain under FDA review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XSpray Pharma AB (publ) published the original content used to generate this news brief on September 23, 2026, and is solely responsible for the information contained therein.